Member Info for EmeraldCarrots

....

Might succeed. I can't be bothered to explain anymore. Last Januaries 32p share price was not based on fiction, and will without doubt be surpassed in the next 6 months and by more than double. I'll give you a hint. Look at the RNS's of 2nd Jan and 4th Jan 2024. Both these RNS's conclusions have now been independantly verified. The market is not on the ball, or even in the right stadium at the moment.

All IMHO.

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=GDR.L

I will be the one laughing all the way to the bank I think, while non holders will be sobbing their eyes out.

Last Fridays announcement:-

https://www.londonstockexchange.com/news-article/AGL/her2-presentation-at-sabcs/16811122

Previous Eisai Inc. announcement:-

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

Just spent an hour understanding the poster.

Https://angleplc.com/wp-content/uploads/2024/12/SABCS2024_Poster_HER2quantification.pdf

It shows Parsortix outperformed Cellsearch by a long, long way.

From the poster “The developed pipeline was able to count and identify HER2-positive CTCs with higher efficiency than the gold-standard CellSearch® overall and interestingly, also in the IHC HER2-negative subgroup.".

This confirms the urgent need to test patients shortly before their treatment begins to ensure they are not given the wrong treatment after the cancer has changed since the original biopsy. At the moment this simply does not happen anywhere as far as I know. Pretty obvious it needs to start happening as soon as possible. Some people's treatments are targeting HER2 positive, when their cancer has changed to HER2 negative since the original biopsy meaning it wont work. And vice versa.

Now both that university in Athens and Weill Cornell Medicine have confirmed Angle's own assessment that the up-to-date HER2 status of a cancer can be obtained this way.

Eisai Inc. (top 100 Japanese Plc) are already doing a cancer drug trial where Angle Plc will be assessing the patients HER2 status from patients’ blood samples. By any stretch it seems extremely likely, if not certain, that they will find the information from this trial invaluable and need it for phase 3. Also, other Companies doing breast cancer drug trials surely will now want this service as well? I am shocked that so far only Eisai Inc. have contracted Angle to assess the HER2 status during an actual cancer drug trial. To me it is utterly astonishing no other multibillion $ Pharma Co’s have followed Eisai’s lead which Weill Cornell Medicine have now shown was the right call.

People on this bb. Have posted they think I am crazy to think Angle Plc will get bought out for North of 60p a share. What do you think now?

All IMHO.

Https://angleplc.com/wp-content/uploads/2024/12/SABCS2024_Poster_HER2quantification.pdf

From the poster:-

Conclusions.

▪ The current study shows the feasibility of a real time HER2 assessment on CTCs enriched from

BC pts.

▪ The developed pipeline was able to count and identify HER2-positive CTCs with higher efficiency than

the gold-standard CellSearch® overall and interestingly, also in the IHC HER2-negative subgroup. This

is a preliminary analysis that should be confirmed in larger cohorts.

▪ HER2 marker is a therapeutic target and an accurate and real-time assessment of the HER2 status

could be used to better guide treatment in a larger cohort of patient with advanced breast cancer with

any detectable HER2 expression that can be effectively treated with antibody-drug conjugates.

=====================================

The Eisai Inc. HER2 cancer drug trial is ongoing and this poster gives every reason to think Angle's involvement will reap £ millions in the coming years. Angle's RNS of 2nd Jan 2024:-

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

Believe now?????

What more does the market need!!!!!!!!!!!!!!!

All IMHO.

Https://angleplc.com/wp-content/uploads/2024/12/SABCS2024_Poster_HER2quantification.pdf

Parsortix IS HERE !!!!!!!!!!

Up 9.76%

Liamcossie

I don’t understand why things are getting published or late as ‘non rns’ - this is only limiting the people who can see the news / updates ?

========================

Maybe deliberately surpressing the sp before the big RNS? Last Jan 4th the sp leaped up to 32p a share from 12p in 2 days. See chart.

When this one blows it will be like a Saturn V rocket to the Moon. All it would take is Eisai, or Astrazeneca to move to the next stage with the existing contracts.

All IMHO.

Liamcossie.

"Thanks for the informative posts carrot :)"

=======================

I honestly think the biggest Pharma co's are incredibly S L O W to do ANYTHING! Proof of this tech is there and has been for at least a few YEARS! More and more papers back it up and STILL they do little or nothing. It's disgraceful it takes a year or two for these Companies to act. I think the top 100 Japanese Co. Eisai Inc. have got ma massive lead over other huge Pharma now. Even that took about a year to negotiate apparently. Astrazeneca got on board 6 months later and the others, I presume are too busy having meetings to endlessly talk about the possibility of maybe looking into this tech that is staring them in the face. Are they total idiots?

All IMHO.

It's very simple. The LIVE circulating tumor cells that Angle Plc's parsortix machine can catch from a standard blood sample will lead to vastly increased and better targeted sales of the drugs THEY ALREADY SELL. They need to do the math as thay say in the USA. If they want to make even more billions of $ then then need to embrace the tech Angle Plc have.......... like Eisai Inc. ALREADY have, with Angle. Astrazeneca too of course, already...... Take you time though. No rush....

https://www.londonstockexchange.com/news-article/AGL/her2-presentation-at-sabcs/16811122

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

All IMHO.

All IMHO.

Here yet. It is incredibly frustrating the sp is so low at the moment. The below announcement FURTHER proves that catching circulating tumor cells (CTC's) using Angle Plc's Parsortix machine from a standard blood sample will be worth HUNDREDS OF MILLIONS OF POUNDS in due course. Measuring the HER2 status of a cancer using this method is just ONE of the biomarkers that can be measured using live CTC's. JUST ONE!!

https://www.londonstockexchange.com/news-article/AGL/her2-presentation-at-sabcs/16811122

The market is asleep at the wheel on this BIGTIME. Do the research and see for yourself.

A screaming, screaming buy if ever there was one.

All IMHO.

Up 10% !

Up to date status can be measured using circulating tumor cells.!! This is extremely significant. This is a World renowned institition. This means Pharma Co's could offer their cancer drugs to more people if they are tested in this way!! Roll of the results from Eisai Inc. who are already progressing this in a real cancer drug trial as we know................

=====================

Dr. Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine, Weill Cornell Medicine commented:

"We are pleased to present further data validating our workflow which enables quantitative and semi-automated assessment of HER2 in CTCs. HER2 is a major therapeutic target and an accurate and real-time assessment of HER2 status could be used to monitor CTCs over time to better guide treatment and identify patients with any detectable HER2 expression, or changes to HER2 expression, who could benefit from treatment with ADCs.

This methodology has the potential to be applied to a wide range of biomarkers and our ultimate goal is to develop automated workflows which enable longitudinal CTC assessment of biomarker status for targeted treatment selection or to predict treatment response."

====================

Alll IMHO.

RNS seconds ago.

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM

Up 7.32%.

No reason why not if customer signs disclaimer. I see Chemists all over the World ofering this sort of service. Why not? Come on Boots the chemist? You are sitting on a gold mine with your 3000 branches in the UK alone. Get on with it!

All IMHO.

That Genedrive offer. Customer signs disclaimed at the moment......................

Up 6.1%

Up 4.8%, news out?

Up 4.8% already